SLC6A2 and neuroblastoma: ALK is also the target of various immunotherapeutic strategies in preclinical development, including CARs13,14 and antibody–drug conjugates (ADCs).15 The norepinephrine transporter (NET, encoded by SLC6A2) is another protein of interest that is used for both imaging and therapeutic purposes.2 Radiolabeled 131I-MIBG, which is shuttled into neuroblastoma tumor cells by the NET overexpressed on the cell surface, is also being studied in the same Phase 3 trial as lorlatinib.